You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

How does the 30-day cost of Relvar for the treatment of asthma compare to other ICS/LABA combination inhalers?

Please click on the thumbnail to the left to view and download a pdf copy of a cost comparison chart of ICS/LABAs available for the treatment of asthma. Relvar Ellipta low-mid dose (92/22mcg) and high dose (184/22mcg) are highlighted in orange.

The cost comparison chart is updated regularly to reflect the change in list price of ICS/LABAs inhalers.

If you would like to estimate the potential financial impact of adopting Relvar Ellipta for the treatment of asthma in your health economy please contact a Health Outcomes Consultant (HOC). The HOC will model and localise the estimate using prescribing data for your own health economy.

To arrange a meeting with a HOC use the following link:

uk.hoc-on-demand@gsk.com

Please state your preference to either meet in person, telephone or on-line.

Please note: Dose categories are as per the BTS/SIGN asthma guideline.[1]

Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events.[2]

References:

  1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2016. Available at: https://www.brit-thoracic.org.uk
  2. Summary of Product Characteristics. Available at: http://medicines.org.uk/emc/  

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies